J&J Zarnestra Efficacy Rate Likely To Be Focus Of Oncology Cmte. Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA finds lower rate of complete responses in acute myeloid leukemia patients compared to Johnson & Johnson's analysis. Zarnestra (tipifarnib) oral dosing and low side-effect profile compared to standard chemotherapy may prove positive in the committee's evaluation.